Aktuellt
SENASTE
Redeye see's an uplifting Q3 2023 report from Stille, which came in above our estimates both in terms of sales and EBIT, we note a particularly strong growth in the surgical instruments unit (+27% y/y). Considering that Q4 historically proves to be a robust quarter for Stille, we find the outlook for the share to be promising and believe it will trade up on today's report.
LÄS MER
